Gastroesophageal Reflux DiseaseNCT05614752
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
An observational study of Gastroesophageal Reflux Disease, run by Daewoong Pharmaceutical Co. LTD. at 1 site in South Korea.
Trial summary
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet. Read more about this study
- Who is it for?
- Ages 19 to 75 years
- Conditions the study is for
- Gastroesophageal Reflux Disease
- What is being tested?
- Fexuprazan
- Type of treatment
- Pill or oral medicine
- How many people
- 10,067 participants
- Where
- 1 siteSouth Korea
- Study dates
- 6 Jul 2022to 8 Nov 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population was calculated by the average of changes and standard deviation at two weeks and by referring to Michael Shaw et al. (2008)'s RDQ score (reverse flow, heartburn, indigestion)
Who may be able to join
- Adult aged 19 years to 75 years (on registration date)
- Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator.
- Patient who agreed to participate in this observation study and signed Informed Consent Form
Who cannot join
- A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet
- Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof
- Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations
- Pregnant and lactating women
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
- A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;
- In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease
This observational study is a large-scale, prospective, and multi-institutional observational study.
Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Read the detailed description
Data will be collected based on patient's medical records from daily visit. Enrolled subjects will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation (GERD-HRQL) and self-awareness symptom (RDQ).
The survey will be done twice (before and after the administration of Fexuclue tablet) electronically through an application (e-PRO).
- Conditions
- Gastroesophageal Reflux Disease
- Being tested
- Fexuprazan
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FexuprazanDrug
Fexuclue Tablet 40mg
| Study group | Role | What they receive |
|---|---|---|
| Treatment group | treated with Fexuclue Tablet 40mg Receives: Drug: Fexuprazan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average score change in RDQ
Average score change in RDQ at least 2 weeks (up to 8 weeks) compared to baseline
Measured: At least 2 weeks (up to 8 weeks)
Secondary outcomes (4)
changes in average score of the individual symptoms (reflux, heartburn, indigestion)
changes in average score of the individual symptoms (reflux, heartburn, indigestion) at least 2 weeks(up to 8 weeks) from baseline (0~5)
Measured: At least 2 weeks (up to 8 weeks)
RDQ validity rate
RDQ validity rate at least 2 weeks(up to 8 weeks) from baseline
Measured: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the subjects
Overall improvement result (scale 1~5, Fully recovered/Much improvement/Moderate improvement/Unchanged/Aggravated) evaluated by the subjects at least 2 weeks(up to 8 weeks) from baseline
Measured: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the researchers
Overall improvement (scale 1~5, Fully recovered/Much improvement/Moderate improvement/Unchanged/Aggravated) evaluated by the researchers at least 2 weeks(up to 8 weeks) from baseline
Measured: At least 2 weeks (up to 8 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2022
- Study start6 Jul 2022
- Primary completion31 Dec 2023
- Study completion8 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastroesophageal Reflux DiseaseStudies of the same condition, open and under way.
- More trials run by Daewoong Pharmaceutical Co. LTD.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 10,067 participants (actual)
Sponsor and investigators
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Seungyoung Seo, Principal investigator, Jeonbuk National University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05614752
- Sponsor's protocol ID
- DWFE_P406
- Status last verified
- Jan 2025
- First submitted
- 7 Nov 2022
- Last updated
- 24 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Not yet decided
Study at a glance
From the registry record, last updated by the sponsor on 24 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease
- ClinicalTrials.gov ID
- NCT05614752
- Acronym / sponsor ID
- DWFE_P406
- Conditions
- Gastroesophageal Reflux Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 10,067 participants (actual)
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry (pharma, biotech, devices)
- Study start
- 6 Jul 2022 (actual)
- Primary completion
- 31 Dec 2023 (actual)
- Study completion
- 8 Nov 2024 (actual)
- First posted
- 14 Nov 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study is a large-scale, prospective, and multi-institutional observational study.
Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Detailed description
Data will be collected based on patient's medical records from daily visit. Enrolled subjects will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation (GERD-HRQL) and self-awareness symptom (RDQ).
The survey will be done twice (before and after the administration of Fexuclue tablet) electronically through an application (e-PRO).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment group | – | Drug: Fexuprazantreated with Fexuclue Tablet 40mg |
Who may qualify
- Ages
- 19 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population was calculated by the average of changes and standard deviation at two weeks and by referring to Michael Shaw et al. (2008)'s RDQ score (reverse flow, heartburn, indigestion)
Key inclusion criteria (3 listed)
- Adult aged 19 years to 75 years (on registration date)
- Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator.
- Patient who agreed to participate in this observation study and signed Informed Consent Form
Key exclusion criteria (7 listed)
- A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet
- A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;
- In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FexuprazanFexuclue Tablet 40mg | Drug | Treatment group |
Primary outcome
Average score change in RDQ
Time frame: At least 2 weeks (up to 8 weeks)
Average score change in RDQ at least 2 weeks (up to 8 weeks) compared to baseline
4 secondary outcomes
changes in average score of the individual symptoms (reflux, heartburn, indigestion)
Time frame: At least 2 weeks (up to 8 weeks)
RDQ validity rate
Time frame: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the subjects
Time frame: At least 2 weeks (up to 8 weeks)
Overall improvement evaluated by the researchers
Time frame: At least 2 weeks (up to 8 weeks)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jan 2025.
- Individual participant dataSharing planned: Undecided. Not yet decided
Related trials for Gastroesophageal Reflux Disease
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
RecruitingObservational study
Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate
Erosive Gastroesophageal Reflux Disease
Recruiting
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
Paraesophageal Hernia, GERD
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
Phrenoesophageal Ligament Reconstruction With Mesh
Hiatus Hernia, Gastreoesophageal Reflux Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Seungyoung Seo principal investigator
Jeonbuk National University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastroesophageal Reflux Disease, run by Daewoong Pharmaceutical Co. LTD. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average score change in RDQ (time frame: At least 2 weeks (up to 8 weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jan 2025.